Site-specific protein modification

Details Site-specific protein modification Site-specific protein modification

2006-04-18

2006-04-18

Campell, Bruce R. (Department: 1654)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving nucleic acid

C514S002600, C436S172000, C530S345000

Reexamination Certificate

active

07029846

ABSTRACT:
Site-specific modified proteins and method for producing site-specific modified proteins using amino acid analogs are disclosed. Methods for labeling proteins at a desired site in the presence of nucleophilic side chains, including lysine and cysteine side chains, are also disclosed. Methods for labeling the site-specific modified proteins are also disclosed.

REFERENCES:
patent: 3714140 (1973-01-01), Sipos
patent: 3715434 (1973-02-01), Mende
patent: 3875207 (1975-04-01), Iselin et al.
patent: 3944538 (1976-03-01), Bodanszky
patent: 4568640 (1986-02-01), Rubin
patent: 5945283 (1999-08-01), Kwok et al.
patent: 5958700 (1999-09-01), Nadeau et al.
patent: 6180347 (2001-01-01), Iida et al.
patent: 6316194 (2001-11-01), Karn et al.
patent: 6503713 (2003-01-01), Rana
patent: 6573045 (2003-06-01), Karn et al.
Odom O. W., Biochemistry 23, 5069, 1984.
Odom O. W., Biochemistry 19, 5947, 1980.
Odom O. W. Biochemistry 19, 1980.
Odom O. W. Biochemistry 23, 1984.
Matsumoto, C., Bioorganic & Medicinal Chemistry Letters (2000), 10(16), 1857-1861.
Tamilarasu, Natarajan, Bioconjugate Chemistry, (Mar.-Apr., 2001) vol. 12, No. 2, pp. 135-138.
Kumagai, Bioorg Med Chem Letters 10, 377 (2000).
Murchie, Alastair, Journal of Molecular Biology, (Feb. 20, 2004) vol. 336, No. 3, pp. 625-638.
Zhang, J. Biol. Chem. 275, 34314, (2000).
Czworkowski J, Biochemistry, (May 14, 1991) 30 (19) 4821-30.
Klostermeier D, Biochemistry, (Oct. 24, 2000) 39 (42) 12970-8.
Odom O W, Biochemistry, (Dec. 4, 1990) 29 (48) 10734-44.
Berkhout et al., “Tat trans-activates the Human Immunodeficiency Virus Through a Nascent RNA Target,” Cell, vol. 59, (Oct. 20, 1989) pp. 273-282.
Calnan et al., “Analysis of arginine-rich peptides from the HIV Tat protein reveals unusual featuures of RNA—protein recognition,” Genes Dev., 5, (1991) pp. 201-210.
Calnan et al., “Arginine-Mediated RNA Recognition: The Arginine Fork,” Science, vol. 252, (May 24, 1991) pp. 1167-1171.
Churcher et al., “High Affinity Binding of TAR RNA by the Human Immunodeficiency Virus Type-1tatProtein Requires Base-pairs in the RNA Stem and Amino Acid Residues Flanking the Base Region,” J. Mol. Biol., vol. 230, No. 1, (Mar. 5, 1993) pp. 90-110.
Clegg, “Fluorescence resonance energy transfer and nucleic acids,” Methods Enzymol., vol. 211, (1992) pp. 353-388.
Cornish et al., “Site-Specific Protein Modification Using a Ketone Handle,” J. Am. Chem. Soc., vol. 118, (1996) pp. 8150-8151.
Cordingley et al., “Sequence-specific interaction of Tat protein and Tat peptides with the transactivation-responsive sequence element of human immunodeficiency virus type 1in vitro,” Proc. Natl. Acad. Sci., vol. 87, No. 22, (Nov. 1990) pp. 8985-8989.
Cullen, “HIV-1 auxiliary proteins: making connections in a dying cell,” Cell, vol. 93, No. 5, (May 29, 1998) pp. 685-692.
Dingwall et al., “Human immunodeficiency virus 1 tat protein binds trans-activation-responsive region (TAR) RNAin vitro,” Proc. Natl. Acad. Sci., vol. 86, No. 18, (Sep. 1989) pp. 6925-6929.
Dingwall et al., “HIV-1tat protein stimulations transcription by binding to a U-rich bulge in the stem of the TAR RNA Structure,” EMBO J., vol. 9, No. 12, (1990) pp. 4145-4153.
Dong et al., “Synthesis and biological activities of fluorescent acridine-containing HIV-1 nucleocapsid proteins for investigation of nucleic acid-NCp7 interactions,” J. Peptide Res., vol. 50, No. 1, (Jul. 1997), pp. 269-278.
Falchetto et al., “The Plasma Membrane Ca2+Pump Contains a Site That Interacts with Its Calmodulin-binding Domain,” J. Biol. Chem., vol. 266, No. 5, (Feb. 15, 1991) pp. 2930-2936.
Geoghegan et al., “Site-Directed Conjugation of Nonpeptide Groups to Peptides and Proteins via Periodate Oxidation of a 2-Amino Alcohol. Application to Modification at N-Terminal Serine,” Bioconjugate Chem. vol. 3, No. 2, (Mar. 4, 1992) pp. 138-146.
Huq et al., “Probing the proximity of the core domain of an HIV-1 Tat fragment in a Tat—TAR complex by affinity cleaving,” Biochemistry, vol. 36, (1997) pp. 12592-12599.
Jakobovits et al. “A discrete Element 3' of Human Immunodeficiency Virus 1 (HIV-1) and HIV-2 mRNA Initiation Sites Mediates Transcriptional Activation by an HIVtransActivator,” Mol. Cell. Biol., vol. 8, No. 6, (May 1988) pp. 2555-2561.
Jones et al., “Control of RNA Initiation and Elongation at the HIV-1 Promoter,” Annu. Rev. Biochem., vol. 63, (1994) pp. 717-743.
Jones, “Taking a new TAK on Tat transactivation,” Genes & Dev., vol. 11, No. 20, (Oct. 15, 1997), pp. 2593-2599.
King et al., “A cleavage method which minimizes side reactions following Fmoc solid phase peptide synthesis,” Int J. Peptide Protein Res., vol. 36, No. 3, (Sep. 1990) pp. 255-266.
Lohse et al., “Fluorescein-Conjugated Lysine Monomers for Solid Phase Synthesis of Fluorescent Peptides and PNA Oligomers,” Bioconjugate Chem., vol. 8, No. 4, (Jul. 8, 1997) pp. 503-509.
Long et al., “Interaction of human immunodeficiency virus type 1 Tat-derived peptides with TAR RNA,” Biochemistry, vol. 34, No. 27, (Jul. 11, 1995) pp. 8885-8895.
Means et al., “Chemical modification of proteins: history and application,” Bioconjugate Chem., vol. 1, No. 1, (Jan. 2, 1990) pp. 2-12.
Muesing et al., “Regulation of mRNA Accumulation by a Human Immunodeficiency VirusTrans-Activator Protein,” Cell, vol. 48, No. 4, (Feb. 27, 1987) pp. 691-701.
Muller et al., “Interaction of fluorescently labeled dideoxynucleotides with HIV-1 reverse transcriptase,” Biochemistry, vol. 30, No. 15, (Apr. 16, 1991) pp. 3709-3715.
Ping et al., “Dynamics of RNA—protein interactions in the HIV-1 Rev-RRE complex visualized by 6-thioguanosine-mediated photocrosslinking,” RNA, vol. 3, No. 8, (Aug. 1997) pp. 850-860.
Ploug et al., “Photoaffinity Labeling of the Human Receptor for Urokinase-Type Plasminogen Activator Using a Decapeptide Antagonist. Evidence for a Composite Ligand-Binding Site and a Short Interdomain Separation,” Biochemistry, vol. 37, (1998) pp. 3612-3622.
Ranganathan et al., “Protein Engineering: Design of Single-Residue Anchored Metal-Uptake Systems,” Inorg. Chem., vol. 38, No. 5, (Mar. 8, 1999) pp. 1019-1023.
Rosen et al., “The Location ofCis-Acting Regulatory Sequences in the Human T Cell Lymphotropic Virus Type III (HTLV-III/LAV) Long Terminal Repeat,” Cell, vol. 41, No. 3, (Jul. 1985) pp. 813-823.
Shah et al., “Synthesis of uridine phosphoramidite analogs: Reagents for site-specific incorporation of photoreactive sites into RNA sequences,” Bioconjugate Chem., vol. 5, (1994), pp. 508-512.
Tinoco et al., “RNA folding,” Nucl. Acids & Mol., Biol. vol. 4, (1990) pp. 205-226.
Wang et al., “RNA conformation in the Tat—TAR complex determined by site-specific photo-cross-linking,” Biochemistry, vol. 35, No. 28, (May 21, 1996) pp. 6491-6499.
Weeks et al., “RNA Recognition by Tat-Derived Peptides: Interaction in the Major Groove?,” Cell, vol. 66, No. 3, (Aug. 9, 1991) pp. 577-588.
Yang et al., “Fluorescence resonance energy transfer as a probe of DNA structure and function,” Methods Enzymol. vol. 278, No. 20, (1997) pp. 417-444.

Affiliated with

Also associated with

Rating

Site-specific protein modification does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Site-specific protein modification, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Site-specific protein modification will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3571446